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Abstract
Background: Non-synonymous single nucleotide polymorphisms (SNPs) within vital DNA repair
genes may cause reduction of activity leaving the genome unrepaired resulting in genomic instability
and cancer.
Materials and methods: The present endeavour involved study on the association of the SNP
rs13181 (Lys751Gln/A18911C) in the Nucleotide Excision Repair (NER) pathway gene ERCC2
(excision repair cross-complementing rodent repair deficiency, complementation group 2) with the
risks of Squamous Cell Carcinomas of the Head and Neck (SCCHN) and Breast cancer using a
case-control based association study among 685 (400 controls and 285 SCCHN-affected cases) and
395 (227 normal healthy female controls and 168 breast cancer cases) ethnically-matched samples,
respectively from north India using Polymerase Chain Reaction followed by Restriction Fragment
Length Polymorphism (PCR-RFLP) analysis.
Results: Results showed significant association of rs13181 homozygous mutant (CC) [Odds Ratio
(OR) 4.412, 95% Confidence Interval (CI) 2.413 to 8.068], heterozygous (AC) (OR 2.086, 95% CI
1.246 to 3.492) and combined mutant (AC + CC) (OR 2.672, 95% CI 1.647 to 4.334) genotypes
with predisposition to Breast cancer. Statistically significant increase in SCCHN risk was also
associated with the mutant genotypes of rs13181 (ERCC2), viz. homozygous mutant (CC) (OR
1.680, 95% CI 1.014 to 2.784), heterozygous (AC) (OR 1.531, 95% CI 1.092 to 2.149) and
combined mutant (AC + CC) (OR 1.560, 95% CI 1.128 to 2.158) genotypes.
Conclusion: The results of this case-control study indicate that the polymorphism rs13181 might
be a risk factor for predisposition towards SCCHN and breast cancer among north Indian
subpopulations.
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Background
Cancer is a genetic disease resulting from gradual accumu-
lation of changes in the DNA that activate proto-onco-
genes and inactivate tumour-suppressor genes leading to
genetic instability which is further aggravated by DNA
damage and errors made by the DNA maintenance and
repair machinery [1]. Many cancers are heritable due to
inheritance of specific variant allele/polymorphic variants
[2-5]. Recent advancements in cancer research have pro-
vided increasing evidences that cancer acts through the
interplay of high-risk variants in a set of low- and
medium-penetrance genes rather than a few high pene-
trance genes [6,7]. The ability to metabolize carcinogens
or pro-carcinogens, repair DNA damage and control cell
signalling and the cell cycle are important examples of
low- and medium-penetrance genes fundamental to
homoeostasis which is why most cancers, including Squa-
mous Cell Carcinomas of the Head and Neck (SCCHN)
and Breast Cancer are based on these main factors [8,9].
SCCHN is the 5th most common cancer worldwide [9]
with high mortality ratios among all malignancies
accounting for 12% of all cancers in men and 8% of all
cancers among women [10]. SCCHN are the commonest
forms of cancers of the head and neck that start in the cells
forming the lining of the mouth, nose, throat and ear or
the surface covering the tongue. The major head and neck
sites include the oral cavity, the pharynx (nasopharynx,
oropharynx and hypopharynx), the tongue (anterior 2/3rd
and posterior 1/3rd or base of tongue), the larynx and the
paranasal sinuses. Breast cancer is the primary subtype of
cancer leading to death among women in developing
countries. 13% out of the 58 million deaths worldwide in
the year 2005 were caused due to cancer which included
502,000 deaths per year due to breast cancer. Well-estab-
lished risk factors ascribed to breast cancer include early
menarche, late menopause, age of first child's birth, nulli-
parity and family history (FH) [11].
DNA repair is considered to play a key role in cancer sus-
ceptibility whereby some individuals are at very high risk
of cancer due to SNPs in crucial DNA repair genes [12-15].
Inactivation or defect in DNA repair genes may be associ-
ated with increased cancer risk [16]. Genetic polymor-
phisms in DNA repair genes are very common events [17-
19], and some studies have shown a significant effect of
some of these polymorphisms in DNA repair capacity [20-
22]. Evidence of inherited abnormalities in DNA repair
genes and genes controlling carcinogen metabolism has
been found to underline increase in risk of cancers [23].
The gene ERCC2 (located in the chromosomal location
19q13.3; OMIM ID 126340; Gene ID 2068; Gene length
18984) encodes the ERCC2/Xeroderma pigmentosum
Type D (XPD) protein, which is one of the seven genetic
complementation groups that forms an essential compo-
nent of the Nucleotide excision repair (NER) pathway, a
major DNA repair pathway that removes photoproducts
from UV radiation and bulky adducts from a huge
number of chemicals, cross-links and oxidative damage
through the action of 20 proteins and several multipro-
tein complexes [13,24]. XPD is a highly polymorphic gene
and correlation of its polymorphisms and cancer risk have
been extensively studied [20,25]. Among the genetic pol-
ymorphisms in ERCC2, the SNP causing amino acid
change in codon 751 (Lys to Gln) (SNP ID rs13181) have
been considered very important and there is evidence that
subjects homozygous for the variant genotypes of XPD
have suboptimal DNA repair capacity for benzo(a)pyrene
adducts and UV DNA damage [26,27]. The polymor-
phism rs13181 has been found to be functionally signifi-
cant since studies have showed that it is associated with
alterations in DNA repair efficiency [16,25,26,28-33].
Therefore, rs13181 has been studied for its role in various
cancers as potential susceptibility factors [23,27,31,34-
48], although no such report is available on the north
Indian subpopulation cluster for the risks of SCCHN or
Breast cancer.
In the present study, genetic association of the nonsynon-
ymous SNP rs13181 with the risks of Breast cancer and
Squamous Cell Carcinomas of the Head and Neck
(SCCHN) was analysed using Polymerase Chain Reaction
followed by Restriction Fragment Length Polymorphism
(PCR-RFLP) in a subpopulation cluster-matched (Indo-
European linguistic subgroup + Caucasoid morphological
subtype) case-control based study among north Indians.
Materials and methods
Case and control sample collection
Blood samples (2 ml each) were collected following writ-
ten informed consent from 168 Breast cancer patients and
285 SCCHN patients, following histopathological and
cytological confirmation, from different parts of north
India undergoing treatment at Lucknow Cancer Institute
(LCI) and Sanjay Gandhi Post Graduate Institute of Med-
ical Sciences (SGPGIMS) between September, 2005 and
June, 2008. 400 (173 males and 227 females) unrelated
ethnically-matched (linguistic and morphological sub-
population clusters) cancer-free blood donors from the
north Indian states of Uttar Pradesh and Uttarakhand
were included in the current study as healthy normal con-
trols for cancer association studies. All the subjects
inducted in this study belonged specifically to the Cauca-
soid morphological subtype [49] and Indo-European lin-
guistic group [50] of north India. A questionnaire was
filled by each subject providing information on gender,
addiction (smoking, tobacco chewing, pan masala), race,
ethnicity, education, religion, marital status, first-degree
family history, history of benign disease, menopausal sta-
tus (for women), etc. Information on tumour subtype, ER-Journal of Experimental & Clinical Cancer Research 2009, 28:104 http://www.jeccr.com/content/28/1/104
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PR status (for breast cancer patients), grading and stage of
disease were obtained from medical records of the
patients. All Breast cancer patients were non-smokers. The
study was approved by Institutional Medical Ethics Com-
mittee of Central Drug Research Institute (CDRI).
DNA Isolation from cancer samples
DNA was isolated from blood samples of SCCHN and
Breast cancer cases and controls using QIAamp DNA
Blood Midikit (Qiagen Inc.) following manufacturer's
protocol, quantitated using spectrophotometer (Gene-
quant pro, Amersham Biosciences) and stored at -20°C.
Primer Designing and synthesis
Reference sequence of the gene ERCC2 and information
on coding regions (CDS) were retrieved from NCBI's
(National Center for Biotechnology Information)
sequence databases. The primers 5' CCCCCTCTCCCTT-
TCCTCTGTTC 3' (Forward Primer) and 5' GGACCT-
GAGCCCCCACTAACG 3' (Reverse Primer) were designed
for the present study on the SNP rs13181 (ERCC2) using
PrimerSelect module of Lasergene v6.0 software (DNAS-
tar). The primer sequences were verified using NCBI
BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi and UCSC
In-silico PCR http://genome-mirror.duhs.duke.edu/cgi-
bin/hgPcr to eradicate the possibility of amplification of
any non-specific DNA sequences and synthesized com-
mercially.
PCR Standardization and Amplification
Gradient PCR reactions were performed for standardiza-
tion of DNA amplification conditions and optimization
of annealing temperature for the set (forward + reverse) of
primers. Briefly, the primer set was used to amplify a
standard DNA template at different annealing tempera-
tures (with increment of approximately 2°C) and the tem-
perature at which highest amount of PCR product was
formed (as visualised from agarose gel) was considered
the optimum annealing temperature for further PCR reac-
tions.
All PCR reactions were performed in 200 μl transparent
PCR tubes (Axygen Scientific Pvt. Ltd.) on a peltier-based
thermal cycler (PTC100, MJ Research) using reagents from
Fermentas Life Sciences in a total reaction volume of 50 μl
containing nearly 100 ng genomic DNA, 1.5 U Taq
polymerase in 1× PCR buffer, 1.5 mM MgCl2, 0.2 mM
dNTPs, and 15 pmol of each primer. Thermal cycling con-
ditions were as follows: initial denaturation step at 95°C
for 10 min, 31 cycles of PCR consisting of denaturation at
94°C for 1 min, annealing at 63.0°C for 1 min and exten-
sion at 72°C for 1 min, followed by a final extension step
at 72°C for 5 min. The reaction was held at 4°C. The PCR
products were visualized by electrophoresis on 1.2% aga-
rose gel and stored at 4°C. For gel electrophoresis, 5 μl of
the amplified product was mixed with 1 μl of 6× gel load-
ing buffer (analytical grade water containing 30% glyc-
erol, 0.25% bromophenol blue, 0.25% xylene cynole)
and resolved on 1.2% agarose gel in TAE buffer at 85 volts
for 1 1/2 hrs. 100 bp DNA markers (New England
Biolabs) were run with the amplified products as refer-
ence.
RFLP analysis for cancer association study
The restriction enzyme PstI (Fermentas Life Sciences) was
selected for PCR-RFLP studies using SeqBuilder module of
Lasergene 6.0 (DNAStar) and WATCUT http://wat
cut.uwaterloo.ca/watcut/watcut/template.php, an on-line
tool for SNP-RFLP analysis. The 413 bp PCR product was
subjected to restriction digestion using PstI following
optimum reaction conditions as per manufacturer's pro-
tocols. The digestion products were visualized by electro-
phoresis on 3% agarose gel for RFLP analysis and the
genotypes were inferred from the number of bands
observed in the gel. The homozygous wild type (AA) gen-
otype generated a single band of 413 bp upon restriction
digestion, the homozygous mutant genotype (CC) pro-
duced two bands of 322 bp and 91 bp, while the hetero-
zygous genotype (AC) was inferred by the presence of all
the three bands (413 bp, 322 bp and 91 bp) upon visual-
isation on agarose gel following restriction digestion
using the enzyme PstI.
Statistical Analysis for determination of genetic 
association
Maximum likelihood estimates of descriptive statistics
like allele and genotype frequencies were calculated using
Microsoft Excel. Further statistical analysis of data was
performed using the computer softwares Statistical Pack-
age for the Social Sciences (SPSS) version 16.0 and Graph-
Pad Prism version 5.0. Hardy-Weinberg Equilibrium
(HWE) was tested online using Hardy-Weinberg Equilib-
rium Calculator http://www.changbioscience.com/genet
ics/hardy.html among cases and controls separately, com-
paring the observed allele counts with that of the
expected, by means of Goodness-of-fit Chi square test at
df (degrees of freedom) = 1. 3 × 2 Contingency Chi-square
test was performed to verify overall association of the gen-
otypes between cases and controls. Odds ratios (OR), rel-
ative risk (RR) and corresponding 95% confidence
intervals (CI) were estimated to ascertain association of
individual genotypes with SCCHN and Breast cancer risks.
Logistic regression was performed to calculate adjusted
ORs for subsequent analysis of potential risk factors like
gender, smoking, Tobacco chewing and pan masala. All
statistical tests were two-sided.
Results
Breast Cancer
Genotype results were successfully obtained among 215
female controls and 155 breast cancer cases. Chisquare-
HWE for genotype distributions were 0.2488 among con-Journal of Experimental & Clinical Cancer Research 2009, 28:104 http://www.jeccr.com/content/28/1/104
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trols. Genotype and allele frequencies for the loci rs13181
(ERCC2) among Breast cancer cases and normal healthy
female controls have been provided in Tables 1 and 2,
respectively. Allele frequencies of mutant allele [C] were
38.1% in control group and 57.1% in breast cancer group.
The corresponding 3 × 2 contingency Chisquare value was
24.39 (P < 0.0001) for the genotypes of rs13181 (ERCC2)
which suggested an overall significant association
between breast cancer incidences and genotypes for the
loci rs13181 (ERCC2). Subsequent analysis concerned
assessment of risks associated with individual mutant
genotypes, WM (heterozygous), MM (homozygous
mutant) and WM + MM (combined mutant) with the risk
of breast cancer based on Odds ratio (OR), 95% Confi-
dence Intervals (CI) and corresponding P values.
Statistically significant association with breast cancer sus-
ceptibility was observed for the mutant genotypes of the
polymorphism rs13181 in the gene ERCC2 viz.
homozygous mutant (CC) (OR 4.412, 95% CI 2.413 to
8.068), heterozygous (AC) (OR 2.086, 95% CI 1.246 to
3.492) and combined mutant (AC + CC) (OR 2.672, 95%
CI 1.647 to 4.334). Results of association studies between
the mutant genotypes and breast cancer risk are repre-
sented in terms of corresponding Odds ratios in Table 3.
The association with breast cancer did not vary greatly
with menopausal status. Analyses stratified by tumour
grading and ER-PR status did not seem to modify the risk
of breast cancer among carriers (data not shown).
Squamous Cell Carcinomas of the Head and Neck 
(SCCHN)
Genotype results were successfully obtained among 385
healthy unaffected control subjects and 275 SCCHN-
affected cases for rs13181 (ERCC2). ChisquareHWE  for
genotype distributions was 0.345 among controls. The
genotype and allele frequencies of the SNP rs13181
(ERCC2) among SCCHN cases and healthy control sub-
jects are provided in Tables 4 and 5, respectively. Mutant
allele frequencies were 34.4% among the controls and
41.1% among SCCHN cases. The corresponding 3 × 2
contingency Chisquare value was 7.417 (P = 0.0245)
which implied an overall significant association between
the prevalence of SCCHN and genotypes of the loci
Table 2: Details of allele frequencies of the SNP rs13181 (ERCC2) observed in normal female and breast cancer samples.
rs13181 (ERCC2)
Allele Frequencies
Normal Female Breast Cancer
W (A) 266 0.619 133 0.429
M (C) 164 0.381 177 0.571
430 310
[W-Wild type allele; M-Mutant allele]
Table 1: Details of genotype frequencies of the SNP rs13181 (ERCC2) among normal female and breast cancer subjects.
rs13181 (ERCC2)
Genotype Frequencies
Normal Female Breast Cancer
WW (AA) 84 0.391 30 0.194
WM (AC) 98 0.456 73 0.471
MM (CC) 33 0.153 52 0.335
WM+MM (AC+CC) 131 0.609 125 0.806
215 155
[WW-homozygous wild type; WM-heterozygous; MM-homozygous mutant]Journal of Experimental & Clinical Cancer Research 2009, 28:104 http://www.jeccr.com/content/28/1/104
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rs13181 (ERCC2). Subsequent analysis pertaining to the
assessment of risks associated with individual mutant
genotypes with regards to SCCHN risk depicted statisti-
cally significant association for rs13181 (ERCC2)
homozygous mutant (CC) (OR 1.680, 95% CI 1.014 to
2.784), heterozygous (AC) (OR 1.531, 95% CI 1.092 to
2.149) and combined mutant (AC + CC) (OR 1.560, 95%
CI 1.128 to 2.158) genotypes. Results of genetic associa-
tion study with SCCHN risk presented in terms of crude
odds ratios of mutant genotypes and adjusted odds ratios
(AOR), adjusted for gender and habits like smoking,
tobacco chewing and pan masala are shown in Table 6.
Association of the selected SNPs with SCCHN risk did not
vary greatly with tumour grading (data not shown).
Discussion
The ERCC2/XPD protein functions as an ATP-dependent
5'-3' helicase joint to the basal TFIIH complex and partic-
ipates in the local unwinding of DNA helix to allow RNA
transcription machinery to access the promoter and to
permit the NER machinery to access the lesion [51,52].
Several studies suggest that XPD protein may participate
in the repair of ionizing radiation-induced oxidative dam-
age [53,54]. The ERCC2 polymorphism, rs13181 located
in exon 23, which consists of an A to C substitution in the
coding region results in a Lys751Gln substitution in the
important domain of interaction between XPD protein
and its helicase activator, inside the TFIIH complex [55]
which is indicative of a possible involvement of this SNP
in defective activity of the gene.
Literatures evaluating the risk of rs13181 (ERCC2/XPD)
polymorphism with the risk of Breast cancer have been
controversial. Although some studies found no correla-
tion between this polymorphism and breast cancer risk
[39,56-59], significant association between rs13181
mutant (C) allele and overall breast cancer risk was found
in some studies. While Terry et al observed a 20% increase
in Breast cancer risk associated with genotypes having at
least one variant allele (OR 1.21), both Terry et al and Ber-
nard-Gallon et al observed a positive correlation of
rs13181 heterozygous genotype with the risk of Breast
cancer upon consideration of interactions between the
mutant genotypes and anthropometric or lifestyle factors
[60,61]. Correspondingly, the present study on the associ-
ation of the SNP rs13181 with predisposition to Breast
cancer showed a significant to highly significant positive
association of greater than 2-folds for the rs13181
homozygous mutant (CC) (OR 4.412, 95% CI 2.413 to
8.068, P < 0.0001), heterozygous (AC) (OR 2.086, 95%
CI 1.246 to 3.492, P = 0.0056) and combined mutant (AC
+ CC) (OR 2.672, 95% CI 1.647 to 4.334, P < 0.0001)
genotypes.
On the other hand, only two studies have been found to
have been conducted so far on the assessment of the risk
of SCCHN associated with rs13181 (ERCC2) mutant gen-
otypes. Both of these studies exhibited significant positive
association with SCCHN risk among non-Hispanic white
Table 5: Details of allele frequencies of the SNP rs13181 
(ERCC2) observed in normal and SCCHN samples.
rs13181 (ERCC2)
Allele Frequencies
Normal SCCHN
W (A) 505 0.656 324 0.589
M (C) 265 0.344 226 0.411
770 550
[W-Wild type allele; M-Mutant allele]
Table 4: Details of genotype frequencies of the SNP rs13181 
(ERCC2) among normal and SCCHN subjects.
rs13181 (ERCC2) Genotype Frequencies
Normal SCCHN
WW (AA) 163 0.423 88 0.320
WM (AC) 179 0.465 148 0.538
MM (CC) 43 0.112 39 0.142
WM+MM (AC+CC) 222 0.577 187 0.680
385 275
[WW-homozygous wild type; WM-heterozygous; MM-homozygous 
mutant]
Table 3: Representation of genetic association of the SNP 
rs13181 in the gene ERCC2 with the risk of breast cancer in 
terms of odds ratios of mutant genotypes.
Genotype OR 95% CI (OR) P Value
WM (AC) 2.086 1.246 to 3.492 0.0056
MM (CC) 4.412 2.413 to 8.068 P < 0.0001
WM + MM (AC+CC) 2.672 1.647 to 4.334 P < 0.0001
[CI-Confidence Interval; OR-Odds Ratio; WW-homozygous wild 
type; WM-heterozygous; MM-homozygous mutant; WM + MM-
combined mutant genotype
WW was considered as the referent category during the calculation 
of ORs.
An OR >1 denotes positive association, while OR <1 signifies 
protective/negative association with cancer risk.]Journal of Experimental & Clinical Cancer Research 2009, 28:104 http://www.jeccr.com/content/28/1/104
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subjects and the south Indian population, respectively
[44,62]. Correspondingly, in the current study, a statisti-
cally significant 1.5 or more-fold increase in SCCHN risk
was associated with all the mutant genotypes of rs13181
(ERCC2), viz. homozygous mutant (CC) (OR 1.680, 95%
CI 1.014 to 2.784, P = 0.0497), heterozygous (AC) (OR
1.531, 95% CI 1.092 to 2.149, P = 0.0167) and combined
mutant (AC + CC) (OR 1.560, 95% CI 1.128 to 2.158, P
= 0.0073) genotypes. Odds ratios adjusted against gender
or habits (smoking, tobacco chewing and pan masala)
using logistic regression also corroborated with the find-
ings made using crude odds ratios only in terms of associ-
ation of these potential risk factors with significant
SCCHN risk demonstrating a potential role of these fac-
tors towards SCCHN susceptibility
Conclusion
The results of the present investigation indicate that the
polymorphism rs13181 might be a risk factor for predis-
position towards SCCHN and Breast cancer among north
Indian subpopulations. The data generated from this
study may have wide-ranging applications for further epi-
demiological and public health related research on the
Indian population.
The degree of susceptibility to cancers is hypothesised to
be the final product of a mishmash of high-risk genetic
polymorphic variants or SNPs in a subset of medium and
low penetrance genes like DNA repair genes which, even
in the absence of the highly penetrant variant cancer-asso-
ciated alleles, may increase the degree of susceptibility
towards cancers a few fold thus having a major impact on
the population incidence of cancer [19]. Therefore, fur-
ther initiatives towards the discovery of cancer susceptibil-
ity SNPs in other genes involved in the NER pathway and
the unravelling of the functional aspects of interactions
between SNP alleles shall be highly beneficial to interpret
these potentially meaningful differences that may be can-
cer-causing and should therefore be vital for revealing the
probable synergistic effect of gene-gene and gene-environ-
ment interactions in cancer susceptibility.
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